Revenge Of The "Brain-Dead Kangaroos": Many Veterans Of 2007 Avandia Vote Come Down Harder On Drug In 2010
• By The Pink Sheet
Accumulating negative information about the cardiovascular risks of GlaxoSmithKline's type 2 diabetes drug Avandia (rosiglitazone) led a much larger number of FDA advisory panel members to recommend taking it off the market than when the same committees met three years earlier
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
